Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,408.50
(
-1.24%
)
US TECH 100
28,244.40
(
-1.90%
)
Dow Jones
49,526.17
(
-1.07%
)
Brent Oil
106.70
(
0.00%
)
Bitcoin
78,619.42
(
-0.56%
)
News Focus
News Focus
Post# of 257579
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122988
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: ghmm post# 76662

Thursday, 04/30/2009 6:16:49 PM

Thursday, April 30, 2009 6:16:49 PM

Post# of 257579
Tidbit from today’s ITMN CC re ritonavir:

In response to a question, Dan Welch said ritonavir boosting of ITMN-191 was not out of the question, but he couldn’t comment on it because such disclosures fall within Roche’s purview.

Welch’s comment contrasts with VRTX’s assertion on its EASL webcast that ritonavir has no value whatsoever in boosting Telaprevir.

Comments?


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today